Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change - Trial NCT06053541
Access comprehensive clinical trial information for NCT06053541 through Pure Global AI's free database. This phase not specified trial is sponsored by Boehringer Ingelheim and is currently Completed. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 1430 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Boehringer Ingelheim
Timeline & Enrollment
N/A
Apr 01, 2021
Jul 01, 2021
Primary Outcome
Occurrence of hospital admissions in Chronic Obstructive Pulmonary Disease (COPD) patients,Number of deaths of hospitalized Chronic Obstructive Pulmonary Disease (COPD) patients,Total costs associated with Chronic Obstructive Pulmonary Disease (COPD) hospitalizations,Infirmary beds
Summary
This study evaluates hospitalizations and mortality in patients with Chronic Obstructive
 Pulmonary Disease (COPD) before and after the implantation of a new COPD treatment plan
 (replacement of tiotropium soft mist inhaler for glycopyrronium dry powder inhaler) by the
 Health State Secretariat of Federal District in Brazil.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06053541
Non-Device Trial